Evidence map›Paper›PMID 31635211›Full record

ArticleMolecules (Basel, Switzerland)2019

Characterization of Redox-Responsive LXR-Activating Nanoparticle Formulations in Primary Mouse Macrophages.

Tyler K T Smith, Zaina Kahiel, Nicholas D LeBlond, Peyman Ghorbani, Eliya Farah, Refel Al-Awosi, Marceline Cote, Suresh Gadde, Morgan D Fullerton

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Association between LXR-Journal of diabetes research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Tyler K T SmithDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, K1H 8M5, Canada. tsmit121@uottawa.ca.ORCID 0000-0002-8013-4660
Zaina KahielDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, K1H 8M5, Canada. zkahi017@uottawa.ca.
Nicholas D LeBlondDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, K1H 8M5, Canada. nlebl062@uottawa.ca.
Peyman GhorbaniDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, K1H 8M5, Canada. pghor093@uottawa.ca.ORCID 0000-0002-7398-5141
Eliya FarahDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, K1H 8M5, Canada. efara031@uottawa.ca.
Refel Al-AwosiDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, K1H 8M5, Canada. ralaw053@uottawa.ca.
Marceline CoteDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, K1H 8M5, Canada. marceline.cote@uottawa.ca.
Suresh GaddeDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, K1H 8M5, Canada. sgadde@uottawa.ca.ORCID 0000-0001-9102-3029
Morgan D FullertonDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, K1H 8M5, Canada. morgan.fullerton@uottawa.ca.ORCID 0000-0002-7221-306X
University of Ottawa · CA

Funding

Canadian Institutes of Health Research MSH141981Canadian Institutes of Health Research PJT148634Heart and Stroke Foundation of Canada ERLI- MDF
6 · The paper itself

Abstract

Activation of the transcription factor liver X receptor (LXR) has beneficial effects on macrophage lipid metabolism and inflammation, making it a potential candidate for therapeutic targeting in cardiometabolic disease. While small molecule delivery via nanomedicine has promising applications for a number of chronic diseases, questions remain as to how nanoparticle formulation might be tailored to suit different tissue microenvironments and aid in drug delivery. In the current study, we aimed to compare the

Indexed as

AnimalsATP Binding Cassette Transporter 1BenzoatesBenzylaminesCells, CulturedDrug CompoundingGene Expression RegulationLiver X ReceptorsMacrophagesMiceNanoparticlesPolyestersPolyethylene GlycolsPrimary Cell CultureAbca1 protein, mouseATP Binding Cassette Transporter 1BenzoatesBenzylaminesGW 3965Liver X ReceptorsPolyesterspolyethylene glycol-poly(lactide-co-glycolide)Polyethylene GlycolsABCA1drug deliveryLXR agonistsmacrophagesnanomedicinenanoparticlesredox-responsive nanoparticle

Identifiers

PMID31635211
PMCPMC6833070
OpenAlexW2980478025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.